Veracyte Inc Cash Flow Conversion Efficiency
Veracyte Inc cash flow conversion efficiency. Based on the latest financial reports, Veracyte Inc (VCYT) has a cash flow conversion efficiency ratio of 0.033x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($45.83 Million) by net assets ($1.39 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Veracyte Inc (2011–2025)
Cash flow conversion efficiency of Veracyte Inc from 2011 to 2025. This chart illustrates how Veracyte Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Veracyte Inc (VCYT) stock price for real-time trading data and today's change.
Veracyte Inc Cash Flow Conversion Ratio Explained
Veracyte Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Veracyte Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Veracyte Inc ranked by their cash flow conversion efficiency. Also see VCYT company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Alliance Resource Partners LP
NASDAQ:ARLP
|
0.086x |
|
Avient Corp
NYSE:AVNT
|
-0.014x |
|
Liechtensteinische Landesbank AG
SW:LLBN
|
0.034x |
|
Baytex Energy Corp
TO:BTE
|
0.107x |
|
Ferrotec (Anhui) Technology Development Co. Ltd. A
SHE:301297
|
N/A |
|
Sino-American Silicon Products
TWO:5483
|
0.031x |
|
Hangzhou Lion Electronics Co Ltd
SHG:605358
|
0.020x |
|
Miami International Holdings, Inc.
NYSE:MIAX
|
0.107x |
Annual Cash Flow Conversion Efficiency for Veracyte Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of Veracyte Inc from 2011 to 2025. Review free cash flow generation of Veracyte Inc to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.31 Billion | $136.31 Million | 0.104x | +62.99% |
| 2024-12-31 | $1.18 Billion | $75.10 Million | 0.064x | +50.77% |
| 2023-12-31 | $1.04 Billion | $44.22 Million | 0.042x | +504.37% |
| 2022-12-31 | $1.08 Billion | $7.54 Million | 0.007x | +124.30% |
| 2021-12-31 | $1.10 Billion | $-31.62 Million | -0.029x | -25.09% |
| 2020-12-31 | $421.23 Million | $-9.71 Million | -0.023x | -70.80% |
| 2019-12-31 | $239.46 Million | $-3.23 Million | -0.013x | +92.04% |
| 2018-12-31 | $79.75 Million | $-13.52 Million | -0.170x | +73.61% |
| 2017-12-31 | $37.23 Million | $-23.91 Million | -0.642x | -36.79% |
| 2016-12-31 | $59.58 Million | $-27.98 Million | -0.470x | +10.73% |
| 2015-12-31 | $51.25 Million | $-26.96 Million | -0.526x | +21.22% |
| 2014-12-31 | $41.37 Million | $-27.63 Million | -0.668x | -96.75% |
| 2013-12-31 | $56.44 Million | $-19.16 Million | -0.339x | +76.79% |
| 2012-12-31 | $4.90 Million | $-7.17 Million | -1.462x | +7.76% |
| 2011-12-31 | $8.53 Million | $-13.52 Million | -1.585x | -- |
About Veracyte Inc
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test… Read more